Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access ranibizumab program for diabetic macular edema in Italy
2011-002731-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Dec 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2011-002731-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002731-26.